Glenmark Pharma reports positive data in Phase 2a study of GBR 830 News News / News 6 years ago 500 Views comments Glenmark Pharmaceuticals announced positive data from a Phase 2a study of GBR 830, an investigational, anti-OX40 monoclonal antibody, in atopic dermat... Read more
News Govt announces global competition to develop cooling technology less harmful to environment than ACs News / News - 5 years ago
Comments